
Sandhya Vasan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5448309/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. Journal of Clinical Investigation, 2022, 132, .	8.2	9
2	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. Current HIV/AIDS Reports, 2022, 19, 86.	3.1	6
3	Neurocognitive impact of Zika virus infection in adult rhesus macaques. Journal of Neuroinflammation, 2022, 19, 40.	7.2	11
4	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 2022, 14, .	12.4	73
5	HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369.	4.7	5
6	Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. AIDS Research and Therapy, 2022, 19, .	1.7	2
7	Cognitive trajectories after treatment in acute HIV infection. Aids, 2021, 35, 883-888.	2.2	13
8	Factors influencing estimates of HIV-1 infection timing using BEAST. PLoS Computational Biology, 2021, 17, e1008537.	3.2	4
9	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathogens, 2021, 17, e1009339.	4.7	32
10	Vaccine development lessons between HIV and COVID-19. Lancet Infectious Diseases, The, 2021, 21, 759-761.	9.1	3
11	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. Frontiers in Immunology, 2021, 12, 710044.	4.8	18
12	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evolution, 2021, 7, veab057.	4.9	2
13	Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. EClinicalMedicine, 2021, 38, 101033.	7.1	4
14	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. PLoS Pathogens, 2021, 17, e1009785.	4.7	12
15	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology, 2021, 95, e0079721.	3.4	2
16	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	44
17	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. Npj Vaccines, 2021, 6, 129.	6.0	47
18	Current approaches to HIV vaccine development: a narrative review. Journal of the International AIDS Society. 2021, 24, e25793.	3.0	35

Sandhya Vasan

#	Article	IF	CITATIONS
19	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. PLoS Pathogens, 2021, 17, e1010105.	4.7	9
20	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proceedings of the United States of America, 2020, 117, 23652-23662.	7.1	193
21	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248.	4.7	33
22	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	3.4	19
23	HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
24	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight, 2020, 5, .	5.0	12
25	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. JCI Insight, 2020, 5,	5.0	12
26	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
27	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	4.7	13
28	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
29	Impact of analytical treatment interruption on the central nervous system in a simian-HIV model. Aids, 2019, 33, S189-S196.	2.2	6
30	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	33
31	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS ONE, 2018, 13, e0196397.	2.5	14
32	HIV Vaccine Efficacy Trials: RV144 and Beyond. Advances in Experimental Medicine and Biology, 2018, 1075, 3-30.	1.6	6
33	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
34	DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. Journal of Immunology, 2017, 199, 3437-3452.	0.8	7
35	<scp>CD</scp> 4+ Cell infiltration into subcutaneous adipose tissue is not indicative of productively infected cells during acute <scp>SHIV</scp> infection. Journal of Medical Primatology, 2017, 46, 154-157.	0.6	22
36	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38

Sandhya Vasan

#	Article	IF	CITATIONS
37	Transgender populations and HIV: unique risks, challenges and opportunities. Journal of Virus Eradication, 2016, 2, 87-93.	0.5	29
38	Transgender populations and HIV: unique risks, challenges and opportunities. Journal of Virus Eradication, 2016, 2, 87-93.	0.5	17
39	Vaccine Induced Seroreactivity in RV144 Vaccine Recipients in RV305, a Placebo Controlled Assessment of Late Boosts with ALVAC-HIV and AIDSVAX B/E. AIDS Research and Human Retroviruses, 2014, 30, A191-A191.	1.1	0
40	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). AIDS Research and Human Retroviruses, 2014, 30, A33-A33.	1.1	11
41	RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. AIDS Research and Human Retroviruses, 2014, 30, A264-A264.	1.1	4
42	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the α4β7-Binding V2 Loop of HIV gp120 in Healthy Volunteers. Vaccine Journal, 2012, 19, 1557-1559.	3.1	36
43	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE, 2011, 6, e19252.	2.5	160
44	Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine. PLoS ONE, 2010, 5, e8617.	2.5	41
45	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. PLoS ONE, 2010, 5, e8816.	2.5	47
46	Unique HIV Risk Factors and Prevention Needs for Transgender Women and Cisgender Men Who Have Sex with Men in Bangkok, Thailand. Transgender Health, 0, , .	2.5	0
47	Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection. Clinical Infectious Diseases, 0, , .	5.8	5